A new study published in Nature identifies a subset of CD8+ T regulatory cells that rely on the receptor GPR15 to control inflammation in the gut. These cells appear to play a key role in maintaining intestinal immune balance, according to the research.
The findings offer a potential target for treating inflammatory bowel diseases such as Crohn's and ulcerative colitis. By understanding how GPR15 guides these suppressive cells, scientists may develop therapies that enhance their protective effects.
GPR15 acts as a homing receptor, directing the CD8+ T reg cells to inflammatory sites in the intestine. The study demonstrates that these cells reduce tissue damage and inflammation, though exact details on patient numbers or effect sizes were not provided in the source.
This research opens avenues for cell-based therapies that could be more precise than current biologics. If GPR15 signaling can be modulated, it might allow doctors to amplify the body's own anti-inflammatory mechanisms in chronic gut conditions.
The work adds to a growing understanding of how regulatory immune cells patrol different tissues, potentially informing treatments beyond the intestine.